We first broke news to you of XAF5 back in December of last year, unveiling some pretty hefty information about the cream, which may, one day, make blepharoplasty a thing of the past. XAF5 Ointment is a topical cream that’s used under the eyes. Expected to become available some time in 2018, the cream works to fight fat pockets under the eyes, which leads to bags and bulging.
You May Also Like: Bags Vs. Hollows: What's the Difference? The cream was developed by Topokine Therapeutics but was recently acquired by Allergan (the same beauty giant that owns Botox, Latisse and Juvederm) for a reported $85 million. While we hear that the formulation isn’t changing due to the sale of Topokine Therapeutics, the brand further adds to Allergan’s prestigious roster of aesthetic products. “The acquisition of Topokine and its XAF5 technology adds an innovative technology to Allergan’s industry leading mid-to-late stage pipeline of more than 70 programs and bolsters our leadership in medical aesthetics,” says David Nicholson, executive vice president and president, global brands research and development at Allergan. “XAF5 has the potential to be the first topical fat reduction product for the treatment of steatoblepharon, a condition with no current therapeutic options available to patients. We look forward to continuing the outstanding development work conducted by the Topokine team to bring this innovative medical aesthetic treatment to market,” he says.
The proprietary active ingredient penetrates into the fat to shrink the size of the fat cells in under-eye bags. The smaller the fat cells, the less bagging there is. Results can be seen in about five weeks.
If XAF5 Ointment eventually makes it way to market, it would be the first prescription-strength topical medication of its kind, and, perhaps, one day may be able to replace the need for more invasive procedures and surgery.